serine has been researched along with Bone Cancer in 16 studies
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We recently reported that in Ewing sarcoma, MLL1 (lysine methyltransferase 2A, KMT2A) and menin are overexpressed and function as oncogenes." | 5.48 | Menin regulates the serine biosynthetic pathway in Ewing sarcoma. ( Bankhead, AR; Cierpicki, T; Grembecka, J; Halbrook, CJ; Kerk, S; Klossowski, S; Kremer, D; Lawlor, ER; Lee, HJ; Ljungman, M; Lyssiotis, CA; Magnuson, B; Sud, S; Svoboda, LK; Teh, SSK; Thomas, D; Treichel, S; Zebolsky, A; Zhang, L, 2018) |
| "Since bone metastatic breast cancer is an incurable disease, causing significant morbidity and mortality, an understanding of the underlying molecular mechanisms would be highly valuable." | 5.37 | Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. ( Edgren, H; Guise, T; Käkönen, SM; Kallioniemi, O; Kohonen, P; Nees, M; Pollari, S; Sara, H; Wolf, M, 2011) |
| "We revealed that expression of miR-659-3p was significantly downregulated in osteosarcoma compared with normal bone cells and was inversely correlated with serine-arginine protein kinase 1 (SRPK1) expression." | 4.12 | MiR-659-3p inhibits osteosarcoma progression and metastasis by inhibiting cell proliferation and invasion via targeting SRPK1. ( Gong, Y; Wei, ZR, 2022) |
| "Ewing sarcomas are driven by EWS-ETS fusions, most commonly EWS-FLI1, which promotes widespread metabolic reprogramming, including activation of serine biosynthesis." | 4.02 | EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma. ( Apfelbaum, AA; Bradin, J; Chen, D; Cierpicki, T; Garcia, AX; Grembecka, J; Haarer, E; Hawkins, AG; Jiménez, JA; Kumar, A; Lawlor, ER; Lyssiotis, CA; Nwosu, ZC; Purohit, T; Ruiz, RO; Svoboda, LK, 2021) |
| "Ascochlorin, a prenylphenol antitumor antibiotic, profoundly increases the expression of endogenous p53 by increasing protein stability in the human osteosarcoma cells and human colon cancer cells." | 3.75 | Ascochlorin activates p53 in a manner distinct from DNA damaging agents. ( Chang, HW; Chang, YC; Furukawa, C; Jeong, JH; Kim, CH; Lee, IS; Magae, J; Min, KS; Nakajima, H; Otsuka, K; Park, KK; Taki, K; Tomita, M, 2009) |
| "We recently reported that in Ewing sarcoma, MLL1 (lysine methyltransferase 2A, KMT2A) and menin are overexpressed and function as oncogenes." | 1.48 | Menin regulates the serine biosynthetic pathway in Ewing sarcoma. ( Bankhead, AR; Cierpicki, T; Grembecka, J; Halbrook, CJ; Kerk, S; Klossowski, S; Kremer, D; Lawlor, ER; Lee, HJ; Ljungman, M; Lyssiotis, CA; Magnuson, B; Sud, S; Svoboda, LK; Teh, SSK; Thomas, D; Treichel, S; Zebolsky, A; Zhang, L, 2018) |
| "For the femur bone cancer model, NCTC 2472 tumor cells were injected into the medullary cavity of the distal femur of C3H/HeN mice." | 1.40 | Relief of cancer pain by glycine transporter inhibitors. ( Dohi, T; Kanematsu, T; Kitayama, T; Morita, K; Motoyama, N; Shiraishi, S; Uezono, Y, 2014) |
| "ERα is critical in many breast tumors and is inhibited by antiestrogens such as tamoxifen in cancer therapy." | 1.38 | Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen. ( de Leeuw, R; Houtman, R; Martens, JW; Melchers, D; Michalides, R; Neefjes, J; Rondaij, M; Ruijtenbeek, R; Verwoerd, D, 2012) |
| "Since bone metastatic breast cancer is an incurable disease, causing significant morbidity and mortality, an understanding of the underlying molecular mechanisms would be highly valuable." | 1.37 | Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. ( Edgren, H; Guise, T; Käkönen, SM; Kallioniemi, O; Kohonen, P; Nees, M; Pollari, S; Sara, H; Wolf, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, Y | 1 |
| Wei, ZR | 1 |
| Issaq, SH | 1 |
| Mendoza, A | 1 |
| Kidner, R | 1 |
| Rosales, TI | 1 |
| Duveau, DY | 1 |
| Heske, CM | 1 |
| Rohde, JM | 1 |
| Boxer, MB | 1 |
| Thomas, CJ | 1 |
| DeBerardinis, RJ | 1 |
| Helman, LJ | 1 |
| Jiménez, JA | 1 |
| Apfelbaum, AA | 1 |
| Hawkins, AG | 1 |
| Svoboda, LK | 2 |
| Kumar, A | 1 |
| Ruiz, RO | 1 |
| Garcia, AX | 1 |
| Haarer, E | 1 |
| Nwosu, ZC | 1 |
| Bradin, J | 1 |
| Purohit, T | 1 |
| Chen, D | 1 |
| Cierpicki, T | 2 |
| Grembecka, J | 2 |
| Lyssiotis, CA | 2 |
| Lawlor, ER | 2 |
| Teh, SSK | 1 |
| Sud, S | 1 |
| Kerk, S | 1 |
| Zebolsky, A | 1 |
| Treichel, S | 1 |
| Thomas, D | 1 |
| Halbrook, CJ | 1 |
| Lee, HJ | 1 |
| Kremer, D | 1 |
| Zhang, L | 1 |
| Klossowski, S | 1 |
| Bankhead, AR | 1 |
| Magnuson, B | 1 |
| Ljungman, M | 1 |
| Sen, N | 1 |
| Cross, AM | 1 |
| Lorenzi, PL | 1 |
| Khan, J | 1 |
| Gryder, BE | 1 |
| Kim, S | 1 |
| Caplen, NJ | 1 |
| Ding, J | 1 |
| Li, T | 1 |
| Wang, X | 1 |
| Zhao, E | 1 |
| Choi, JH | 1 |
| Yang, L | 1 |
| Zha, Y | 1 |
| Dong, Z | 1 |
| Huang, S | 1 |
| Asara, JM | 1 |
| Cui, H | 1 |
| Ding, HF | 1 |
| Motoyama, N | 1 |
| Morita, K | 1 |
| Shiraishi, S | 1 |
| Kitayama, T | 1 |
| Kanematsu, T | 1 |
| Uezono, Y | 1 |
| Dohi, T | 1 |
| Wu, Q | 1 |
| Paul, A | 1 |
| Su, D | 1 |
| Mehmood, S | 1 |
| Foo, TK | 1 |
| Ochi, T | 1 |
| Bunting, EL | 1 |
| Xia, B | 1 |
| Robinson, CV | 1 |
| Wang, B | 1 |
| Blundell, TL | 1 |
| Gorska-Ponikowska, M | 1 |
| Perricone, U | 1 |
| Kuban-Jankowska, A | 1 |
| Lo Bosco, G | 1 |
| Barone, G | 1 |
| Jeong, JH | 1 |
| Nakajima, H | 1 |
| Magae, J | 1 |
| Furukawa, C | 1 |
| Taki, K | 1 |
| Otsuka, K | 1 |
| Tomita, M | 1 |
| Lee, IS | 1 |
| Kim, CH | 1 |
| Chang, HW | 1 |
| Min, KS | 1 |
| Park, KK | 2 |
| Chang, YC | 1 |
| Pollari, S | 1 |
| Käkönen, SM | 1 |
| Edgren, H | 1 |
| Wolf, M | 1 |
| Kohonen, P | 1 |
| Sara, H | 1 |
| Guise, T | 1 |
| Nees, M | 1 |
| Kallioniemi, O | 1 |
| Houtman, R | 1 |
| de Leeuw, R | 1 |
| Rondaij, M | 1 |
| Melchers, D | 1 |
| Verwoerd, D | 1 |
| Ruijtenbeek, R | 1 |
| Martens, JW | 1 |
| Neefjes, J | 1 |
| Michalides, R | 1 |
| Tanaka, H | 1 |
| Yoshida, K | 1 |
| Okamura, H | 1 |
| Morimoto, H | 1 |
| Nagata, T | 1 |
| Haneji, T | 1 |
| Whitfield, JF | 1 |
| Morley, P | 1 |
| Willick, G | 1 |
| Langille, R | 1 |
| Ross, V | 1 |
| MacLean, S | 1 |
| Barbier, JR | 1 |
| Barrientes, S | 1 |
| Cooke, C | 1 |
| Goodrich, DW | 1 |
| Mäsiar, PJ | 1 |
| Medeková, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia[NCT04067336] | Phase 1/Phase 2 | 199 participants (Anticipated) | Interventional | 2019-09-12 | Recruiting | ||
| A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation[NCT04065399] | Phase 1/Phase 2 | 440 participants (Anticipated) | Interventional | 2019-11-05 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 other studies available for serine and Bone Cancer
| Article | Year |
|---|---|
MiR-659-3p inhibits osteosarcoma progression and metastasis by inhibiting cell proliferation and invasion via targeting SRPK1.
Topics: 3' Untranslated Regions; Animals; Arginine; Arginine Kinase; Bone Neoplasms; Cell Line, Tumor; Cell | 2022 |
EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Proliferation; Female; Gene Expression Regulation, Neoplast | 2020 |
EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
Topics: Activating Transcription Factor 4; Biosynthetic Pathways; Bone Neoplasms; Cell Line, Tumor; Cell Pro | 2021 |
EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
Topics: Activating Transcription Factor 4; Biosynthetic Pathways; Bone Neoplasms; Cell Line, Tumor; Cell Pro | 2021 |
EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
Topics: Activating Transcription Factor 4; Biosynthetic Pathways; Bone Neoplasms; Cell Line, Tumor; Cell Pro | 2021 |
EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
Topics: Activating Transcription Factor 4; Biosynthetic Pathways; Bone Neoplasms; Cell Line, Tumor; Cell Pro | 2021 |
Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Energy Metabol | 2018 |
EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.
Topics: Amino Acid Transport System ASC; Aminohydrolases; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell | 2018 |
The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation.
Topics: Animals; Autophagy; Azepines; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; E | 2013 |
Relief of cancer pain by glycine transporter inhibitors.
Topics: Animals; Benzamides; Bone Neoplasms; Cell Line, Tumor; Drug Therapy, Combination; Glycine Plasma Mem | 2014 |
Structure of BRCA1-BRCT/Abraxas Complex Reveals Phosphorylation-Dependent BRCT Dimerization at DNA Damage Sites.
Topics: Amino Acid Sequence; Ataxia Telangiectasia Mutated Proteins; Bone Neoplasms; BRCA1 Protein; Carrier | 2016 |
2-methoxyestradiol impacts on amino acids-mediated metabolic reprogramming in osteosarcoma cells by its interaction with NMDA receptor.
Topics: 2-Methoxyestradiol; Antineoplastic Agents; Binding Sites; Bone Neoplasms; Breast Neoplasms; Cell Mov | 2017 |
Ascochlorin activates p53 in a manner distinct from DNA damaging agents.
Topics: Adenosine Triphosphate; Alkenes; Antibiotics, Antineoplastic; Ataxia Telangiectasia Mutated Proteins | 2009 |
Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis.
Topics: Animals; Blotting, Western; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Differentiation; | 2011 |
Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen.
Topics: Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Estrogen Recept | 2012 |
Calyculin A induces apoptosis and stimulates phosphorylation of p65NF-kappaB in human osteoblastic osteosarcoma MG63 cells.
Topics: Apoptosis; Binding Sites; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Humans | 2007 |
Cyclization by a specific lactam increases the ability of human parathyroid hormone (hPTH)-(1-31)NH2 to stimulate bone growth in ovariectomized rats.
Topics: Adenylyl Cyclases; Analysis of Variance; Animals; Bone Development; Bone Neoplasms; Disease Models, | 1997 |
Glutamic acid mutagenesis of retinoblastoma protein phosphorylation sites has diverse effects on function.
Topics: Bone Neoplasms; Cell Cycle; Cell Line; Cyclin-Dependent Kinases; Genes, Retinoblastoma; Glutamic Aci | 2000 |
The role of serine and glutamine in the metabolism of malignant bone tumors and their significance in the diagnosis and prognosis of bone tumors.
Topics: Amino Acids; Biomarkers, Tumor; Bone Neoplasms; Glutamine; Humans; Prognosis; Reference Values; Seri | 1988 |